ALK and neuroblastoma: In children with newly diagnosed high-risk neuroblastoma, clinical trials are ongoing in North America and Europe targeting ALK aberrations by adding ALK-inhibitors to first-line therapy, with molecular profiling transitioning from basic science to validation in the clinic (NCT03126916; NCT04221035).